Ericsson's Annual General Meeting 2026

Ericsson's Annual General Meeting 2026

STOCKHOLM, April 1, 2026 /PRNewswire/ -- Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) (the "Company") held its Annual General Meeting ("AGM") today on March 31, 2026 in Kista, Stockholm. Shareholders were also able to exercise their voting rights...

New General Level Health Claim for Soy in Australia and New Zealand

New General Level Health Claim for Soy in Australia and New Zealand

New Claim Reaffirms the Positive Role of Soy Protein for Heart Health CHESTERFIELD, Mo., March 31, 2026 /PRNewswire/ -- The U.S. Soybean Export Council (USSEC) and Soy Nutrition Institute Global (SNI Global) applaud a new general level soy heart...

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products...

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative...

Weibo Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results and Annual Dividend

Weibo Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results and Annual Dividend

BEIJING, March 18, 2026 /PRNewswire/ -- Weibo Corporation ("Weibo" or the "Company") (Nasdaq: WB and HKEX: 9898), a leading social media in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December...

Wuzhong Power Grid Spatial Layout Plan Finalized to Solidify Foundation for Energy Development

Wuzhong Power Grid Spatial Layout Plan Finalized to Solidify Foundation for Energy Development

WUZHONG, China, March 13, 2026 /PRNewswire/ -- The Power Facility Spatial Layout Plan of State Grid Wuzhong Power Supply Company has been officially reviewed and approved, setting a clear medium- and long-term development blueprint for Wuzhong's...

Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China

Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China

Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China SHANGHAI, March 12, 2026 /PRNewswire/ --...

Elong Power Holding Limited Announces the Change of Effective Date of its 1 for 80 Share Consolidations

Elong Power Holding Limited Announces the Change of Effective Date of its 1 for 80 Share Consolidations

BEIJING, March 7, 2026 /PRNewswire/ -- Elong Power Holding Limited (Nasdaq: ELPW) (the "Company"), a provider of high power battery technologies for commercial and specialty alternative energy vehicles and energy storage systems, announced a share...

sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization

sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization

Amai Proteins announces a major milestone for sweelin® in the U.S. market. The U.S. FDA has completed its review of the GRAS (Generally Recognized as Safe) notice for sweelin® and confirmed it has no safety concerns regarding the use of sweelin® as...

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 16
  • menu
    menu